Supplementary Tables S1 - S2 from Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in &lt;i&gt;IDH2&lt;/i&gt;- and &lt;i&gt;TET2&lt;/i&gt;-Mutant Acute Myeloid Leukemia